Equecabtagene autoleucel for relapsed or refractory multiple myeloma
5 October 2026
Condition
Cancer
-
Published on 05 Oct 2026
Last Updated on 05 Oct 2026
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Equecabtagene autoleucel suspension for intravenous infusion for treating patients 18 years of age and above with relapsed or refractory multiple myeloma who have received at least three prior lines of treatment (including a proteasome inhibitor and an immunomodulatory agent), and have demonstrated disease progression on the last therapy.
Funding status
Equecabtagene autoleucel suspension for intravenous infusion is recommended for inclusion on the MOH Cell, Tissue and Gene Therapy Product (CTGTP) List for the abovementioned indication from 1 December 2026.
Equecabtagene autoleucel should be used in line with the additional clinical criteria listed in the Annex.
Plain English Summary
Multiple myeloma is a type of blood cancer that affects plasma cells in the bone marrow. These cells become abnormal, forming myeloma cells that grow uncontrollably and leave less room for healthy blood cells. This can cause symptoms such as fatigue and frequent infections. Myeloma cells can also affect other parts of the body, causing problems such as bone pain and kidney damage.
Patients who have symptoms will usually receive a combination for different medicines to reduce the number of myeloma cells as much as possible. However, the cancer can sometimes come back after treatment (relapsed) or continue to worsen despite treatment (refractory), and a different treatment may be needed.
Equecabtagene autoleucel is an immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. It is given as a one-time treatment. First, blood is collected from the patient, and T-cells (a type of white blood cell) are separated from the blood. The T-cells are then genetically modified in a laboratory so they can recognise and target B-cell maturation antigen (BCMA), a protein found on the surface of myeloma cells. The modified T-cells are then put back into the patient’s bloodstream via a slow drip into a vein (intravenously), where they can find and attack the myeloma cells.
Equecabtagene autoleucel was recommended for government funding because its benefit justifies its cost compared with current treatment options. It is included on the MOH Cell, Tissue and Gene Therapy Product (CTGTP) List (opens in new tab), with its cost subsidised by 45% to 75% for eligible patients.
